Allogene outlines plan for ~100 ALPHA3 sites by year end as FDA grants RMAT and Fast Track for cema-cel

Allogene has outlined a plan to establish approximately 100 ALPHA3 sites by the end of the year, following the FDA's granting of Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track status for cema-cel. These FDA designations suggest potential for accelerated development of the therapy.